After securing more than $60 million in funding from Immatics Biotechnologies GmbH (Immatics) and the Cancer Prevention and Research Institute of Texas (CPRIT), The University of Texas MD Anderson Cancer Center announced it will join with Immatics in a brand-new venture: the formation of ImmaticOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.